---
title: "Sanofi (SNYNF.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SNYNF.US.md"
symbol: "SNYNF.US"
name: "Sanofi"
industry: "Pharmaceuticals"
datetime: "2026-05-19T20:27:38.621Z"
locales:
  - [en](https://longbridge.com/en/quote/SNYNF.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SNYNF.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SNYNF.US.md)
---

# Sanofi (SNYNF.US)

## Company Overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.sanofi.com](https://www.sanofi.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.53)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 41 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.73% |  |
| Net Profit YoY | 30.10% |  |
| P/B Ratio | 1.24 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 103793892317.60 |  |
| Revenue | 55313938921.68 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 0.00% | D |
| Gross Margin | 72.09% | A |
| Revenue YoY | 13.73% | B |
| Net Profit YoY | 30.10% | B |
| Total Assets YoY | 2.76% | C |
| Net Assets YoY | 4.05% | C |
| Cash Flow Margin | 136.86% | B |
| OCF YoY | 13.73% | B |
| Turnover | 0.00 | E |
| Gearing Ratio | 42.87% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sanofi",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.73%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "30.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.24",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "103793892317.60",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "55313938921.68",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "72.09%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "13.73%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "30.10%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.76%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.05%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "136.86%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "13.73%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "42.87%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 11.76 | 14/190 | 16.92 | 12.08 | 11.50 |
| PB | 1.24 | 60/190 | 1.45 | 1.39 | 1.35 |
| PS (TTM) | 1.88 | 49/190 | 2.42 | 2.29 | 2.13 |
| Dividend Yield | 0.00% | - | 5.20% | 4.99% | 4.66% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2023-12-28T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 85.35 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SNYNF.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SNYNF.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SNYNF.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SNYNF.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**